| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.37 | 1e-27 |
| mRNA | MLN2480 | CTRPv2 | pan-cancer | AAC | 0.5 | 2e-23 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.3 | 5e-19 |
| mRNA | ATRA | CTRPv2 | pan-cancer | AAC | 0.25 | 1e-13 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | 0.24 | 4e-12 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.24 | 2e-11 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.36 | 2e-11 |
| mRNA | tretinoin:carboplatin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.23 | 4e-11 |
| mRNA | (5Z)-7-Oxozeaenol | GDSC1000 | pan-cancer | AAC | 0.2 | 3e-10 |
| mRNA | Sunitinib | CTRPv2 | pan-cancer | AAC | 0.21 | 5e-10 |